{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:16:46Z","timestamp":1771917406499,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11916-018-0662-z","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T04:24:07Z","timestamp":1517804647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Intrathecal Drug Delivery and Spinal Cord Stimulation for the Treatment of Cancer Pain"],"prefix":"10.1007","volume":"22","author":[{"given":"Fangfang","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Jason","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan David","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Urman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"issue":"5","key":"662_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ejpain.2007.09.004","volume":"12","author":"BT Valeberg","year":"2008","unstructured":"Valeberg BT, Rustoen T, Bjordal K, Hanestad BR, Paul S, Miaskowski C. Self-reported prevalence, etiology, and characteristics of pain in oncology outpatients. Eur J Pain. 2008;12(5):582\u201390. https:\/\/doi.org\/10.1016\/j.ejpain.2007.09.004 .","journal-title":"Eur J Pain"},{"issue":"2","key":"662_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11916-017-0613-0","volume":"21","author":"KD Candido","year":"2017","unstructured":"\u2022 Candido KD, Kusper TM, Knezevic NN. New cancer pain treatment options. Curr Pain Headache Rep. 2017;21(2):12. Review of shifting paradigms in cancer pain treatment as well as interventional techniques available for clinical use. https:\/\/doi.org\/10.1007\/s11916-017-0613-0 .","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"662_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.anclin.2016.01.004","volume":"34","author":"JE Sindt","year":"2016","unstructured":"\u2022 Sindt JE, Brogan SE. Interventional treatments of cancer pain. Anesthesiol Clin. 2016;34(2):317\u201339. Review of practical considerations in the techniques used for interventional cancer pain treatment. https:\/\/doi.org\/10.1016\/j.anclin.2016.01.004 .","journal-title":"Anesthesiol Clin"},{"issue":"6","key":"662_CR4","first-page":"399","volume":"3","author":"L Stearns","year":"2005","unstructured":"Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399\u2013408.","journal-title":"J Support Oncol"},{"issue":"2","key":"662_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00000542-197902000-00013","volume":"50","author":"JK Wang","year":"1979","unstructured":"Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979;50(2):149\u201351. https:\/\/doi.org\/10.1097\/00000542-197902000-00013 .","journal-title":"Anesthesiology"},{"issue":"8","key":"662_CR6","first-page":"516","volume":"56","author":"BM Onofrio","year":"1981","unstructured":"Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56(8):516\u201320.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"662_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1213\/ANE.0000000000001702","volume":"124","author":"CR Abrecht","year":"2017","unstructured":"\u2022 Abrecht CR, Greenberg P, Song E, Urman RD, Rathmell JP. A contemporary medicolegal analysis of implanted devices for chronic pain management. Anesth Analg. 2017;124(4):1304\u201310. Analysis of closed malpractice claims related to spinal cord stimulators and intrathecal drug delivery systems. https:\/\/doi.org\/10.1213\/ANE.0000000000001702 .","journal-title":"Anesth Analg"},{"issue":"1","key":"662_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0304-3959(95)00017-M","volume":"63","author":"DF Zech","year":"1995","unstructured":"Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65\u201376. https:\/\/doi.org\/10.1016\/0304-3959(95)00017-M .","journal-title":"Pain"},{"issue":"3","key":"662_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1526-4637.2004.04037.x","volume":"5","author":"AW Burton","year":"2004","unstructured":"Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ 3rd, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med. 2004;5(3):239\u201347. https:\/\/doi.org\/10.1111\/j.1526-4637.2004.04037.x .","journal-title":"Pain Med"},{"issue":"8","key":"662_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ner.12263","volume":"17","author":"TR Deer","year":"2014","unstructured":"\u2022 Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17(8):711\u20135. Review of \u201crefractory pain\u201d and associated terms on the clinical decision to offer implantable therapies as well as argument for new definition. https:\/\/doi.org\/10.1111\/ner.12263 .","journal-title":"Neuromodulation"},{"issue":"3","key":"662_CR11","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.36076\/ppj.2011\/14\/E283","volume":"14","author":"TR Deer","year":"2011","unstructured":"Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283\u2013312.","journal-title":"Pain Physician"},{"issue":"2","key":"662_CR12","first-page":"52","volume":"8","author":"S Brogan","year":"2010","unstructured":"Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol. 2010;8(2):52\u20139.","journal-title":"J Support Oncol"},{"issue":"2","key":"662_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ner.12538","volume":"20","author":"TR Deer","year":"2017","unstructured":"\u2022\u2022 Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, et al. The polyanalgesic consensus conference (pacc): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96\u2013132. Expert consensus on practice guidelines for intrathecal therapies. https:\/\/doi.org\/10.1111\/ner.12538 .","journal-title":"Neuromodulation"},{"issue":"2","key":"662_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11916-013-0391-2","volume":"18","author":"A Gulati","year":"2014","unstructured":"\u2022 Gulati A, Puttanniah V, Hung J, Malhotra V. Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient. Curr Pain Headache Rep. 2014;18(2):391. Review of stepwise approach to implement implantable thearpies for cancer pain. https:\/\/doi.org\/10.1007\/s11916-013-0391-2 .","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"662_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ner.12543","volume":"20","author":"TR Deer","year":"2017","unstructured":"\u2022\u2022 Deer TR, Hayek SM, Pope JE, Lamer TJ, Hamza M, Grider JS, et al. The polyanalgesic consensus conference (pacc): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20(2):133\u201354. Expert consensus on the trialing process for intrathetcal drug delivery prior to implantation. https:\/\/doi.org\/10.1111\/ner.12543 .","journal-title":"Neuromodulation"},{"key":"662_CR16","doi-asserted-by":"crossref","unstructured":"Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17:2404\u201321.","DOI":"10.1093\/pm\/pnw060"},{"issue":"9","key":"662_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/aas.12485","volume":"59","author":"GP Kurita","year":"2015","unstructured":"\u2022\u2022 Kurita GP, Benthien KS, Nordly M, Mercadante S, Klepstad P, Sjogren P. The evidence of neuraxial administration of analgesics for cancer-related pain: a systematic review. Acta Anaesthesiol Scand. 2015;59(9):1103\u201315. Excellent systematic review of existing evidence for intrathecal therapies for cancer pain with detailed tables listing findings and limitations of key studies. https:\/\/doi.org\/10.1111\/aas.12485 .","journal-title":"Acta Anaesthesiol Scand"},{"issue":"19","key":"662_CR18","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","volume":"20","author":"TJ Smith","year":"2002","unstructured":"Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040\u20139. https:\/\/doi.org\/10.1200\/JCO.2002.02.118 .","journal-title":"J Clin Oncol"},{"issue":"5","key":"662_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/annonc\/mdi156","volume":"16","author":"TJ Smith","year":"2005","unstructured":"Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, et al. An implantable drug delivery system (idds) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (cmm). Ann Oncol. 2005;16(5):825\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdi156 .","journal-title":"Ann Oncol"},{"issue":"1","key":"662_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1399-6576.1991.tb03237.x","volume":"35","author":"M Sjoberg","year":"1991","unstructured":"Sjoberg M, Appelgren L, Einarsson S, Hultman E, Linder LE, Nitescu P, et al. Long-term intrathecal morphine and bupivacaine in \u201crefractory\u201d cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand. 1991;35(1):30\u201343. https:\/\/doi.org\/10.1111\/j.1399-6576.1991.tb03237.x .","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"662_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00000542-199402000-00008","volume":"80","author":"M Sjoberg","year":"1994","unstructured":"Sjoberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg\/ml. Anesthesiology. 1994;80(2):284\u201397. https:\/\/doi.org\/10.1097\/00000542-199402000-00008 .","journal-title":"Anesthesiology"},{"issue":"9","key":"662_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/AJP.0b013e3181565d17","volume":"23","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain. 2007;23(9):793\u20138. https:\/\/doi.org\/10.1097\/AJP.0b013e3181565d17 .","journal-title":"Clin J Pain"},{"issue":"6","key":"662_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0269216315570514","volume":"29","author":"A Mitchell","year":"2015","unstructured":"\u2022 Mitchell A, McGhie J, Owen M, Mcginn G. Audit of intrathecal drug delivery for patients with difficult-to-control cancer pain shows a sustained reduction in pain severity scores over a 6-month period. Palliat Med. 2015;29(6):554\u201363. Positive prospective case series evaluating efficacy of intrathecal drug delivery in difficult to control cancer pain. https:\/\/doi.org\/10.1177\/0269216315570514 .","journal-title":"Palliat Med"},{"issue":"11","key":"662_CR24","doi-asserted-by":"publisher","first-page":"e6354","DOI":"10.1097\/MD.0000000000006354","volume":"96","author":"S Zheng","year":"2017","unstructured":"Zheng S, He L, Yang X, Li X, Yang Z. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: a prospective cohort study. Medicine (Baltimore). 2017;96(11):e6354. https:\/\/doi.org\/10.1097\/MD.0000000000006354 .","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"662_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/AAP.0000000000000251","volume":"40","author":"SE Brogan","year":"2015","unstructured":"\u2022 Brogan SE, Winter NB, Okifuji A. Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med. 2015;40(4):369\u201375. Positive prospective study evaluating the clinical response to patient-controlled intrathecal analgesia with respect to pain control and patient satisfaction in cancer pain. https:\/\/doi.org\/10.1097\/AAP.0000000000000251 .","journal-title":"Reg Anesth Pain Med"},{"issue":"7","key":"662_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/jpm.2013.0544","volume":"17","author":"HJ Liu","year":"2014","unstructured":"Liu HJ, Gao XZ, Liu XM, Xia M, Li WY, Jin Y. Effect of intrathecal dexmedetomidine on spinal morphine analgesia in patients with refractory cancer pain. J Palliat Med. 2014;17(7):837\u201340. https:\/\/doi.org\/10.1089\/jpm.2013.0544 .","journal-title":"J Palliat Med"},{"issue":"1","key":"662_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.291.1.63","volume":"291","author":"PS Staats","year":"2004","unstructured":"Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or aids: a randomized controlled trial. JAMA. 2004;291(1):63\u201370. https:\/\/doi.org\/10.1001\/jama.291.1.63 .","journal-title":"JAMA"},{"issue":"5","key":"662_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jpainsymman.2005.10.003","volume":"31","author":"RL Rauck","year":"2006","unstructured":"Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag. 2006;31(5):393\u2013406. https:\/\/doi.org\/10.1016\/j.jpainsymman.2005.10.003 .","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"662_CR29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.36076\/ppj.2012\/15\/395","volume":"15","author":"D Dupoiron","year":"2012","unstructured":"Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmerias F, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012;15(5):395\u2013403.","journal-title":"Pain Physician"},{"issue":"1","key":"662_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pain.2011.10.002","volume":"153","author":"I Alicino","year":"2012","unstructured":"Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain. 2012;153(1):245\u20139. https:\/\/doi.org\/10.1016\/j.pain.2011.10.002 .","journal-title":"Pain"},{"issue":"2","key":"662_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40120-015-0035-z","volume":"4","author":"AB Calle Gil de la","year":"2015","unstructured":"\u2022 de la Calle Gil AB, Pena Vergara I, Cormane Bornacelly MA, Pajuelo Gallego A. Intrathecal ziconotide and morphine for pain relief: a case series of eight patients with refractory cancer pain, including five cases of neuropathic pain. Neurol Ther. 2015;4(2):159\u201368. Positive case series for the combination of morphine and ziconotide for cancer pain treatment. https:\/\/doi.org\/10.1007\/s40120-015-0035-z .","journal-title":"Neurol Ther"},{"issue":"2","key":"662_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.pain.2013.10.015","volume":"155","author":"J Mamet","year":"2014","unstructured":"Mamet J, Klukinov M, Yaksh TL, Malkmus SA, Williams S, Harris S, et al. Single intrathecal administration of the transcription factor decoy ayx1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury. Pain. 2014;155(2):322\u201333. https:\/\/doi.org\/10.1016\/j.pain.2013.10.015 .","journal-title":"Pain"},{"issue":"6","key":"662_CR33","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/j.pain.0000000000000115","volume":"156","author":"DC Brown","year":"2015","unstructured":"Brown DC, Agnello K, Iadarola MJ. Intrathecal resiniferatoxin in a dog model: efficacy in bone cancer pain. Pain. 2015;156(6):1018\u201324. https:\/\/doi.org\/10.1097\/j.pain.0000000000000115 .","journal-title":"Pain"},{"issue":"17","key":"662_CR34","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s40265-015-0471-1","volume":"75","author":"C Smyth","year":"2015","unstructured":"\u2022\u2022 Smyth C, Ahmadzai N, Wentzell J, Pardoe A, Tse A, Nguyen T, et al. Intrathecal analgesia for chronic refractory pain: current and future prospects. Drugs. 2015;75(17):1957\u201380. Excellent detailed review of intrathecal drug therapies and evidence behind use. https:\/\/doi.org\/10.1007\/s40265-015-0471-1 .","journal-title":"Drugs"},{"issue":"2","key":"662_CR35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ner.12384","volume":"19","author":"LJ Stearns","year":"2016","unstructured":"Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA. Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation. 2016;19(2):196\u2013205. https:\/\/doi.org\/10.1111\/ner.12384 .","journal-title":"Neuromodulation"},{"issue":"4","key":"662_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/pme.12060","volume":"14","author":"SE Brogan","year":"2013","unstructured":"Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit. Pain Med. 2013;14(4):478\u201386. https:\/\/doi.org\/10.1111\/pme.12060 .","journal-title":"Pain Med"},{"key":"662_CR37","unstructured":"Ottawa Hospital Research Institute, University of Ottawa, and Health Quality Ontario. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser [Internet]. 2016;16(1):1\u201351. Available from: http:\/\/www.hqontario.ca\/evidence\/publications-andohtac-recommendations\/ontario-health-technology-assessment-series\/hta-cancer-pain ."},{"key":"662_CR38","first-page":"CD009389","volume":"6","author":"L Peng","year":"2015","unstructured":"Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015;6:CD009389.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"662_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1213\/00000539-199307000-00022","volume":"77","author":"K Shimoji","year":"1993","unstructured":"Shimoji K, Hokari T, Kano T, Tomita M, Kimura R, Watanabe S, et al. Management of intractable pain with percutaneous epidural spinal cord stimulation: differences in pain-relieving effects among diseases and sites of pain. Anesth Analg. 1993;77(1):110\u20136.","journal-title":"Anesth Analg"},{"issue":"2","key":"662_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1049909111410414","volume":"29","author":"AE Yakovlev","year":"2012","unstructured":"Yakovlev AE, Resch BE. Spinal cord stimulation for cancer-related low back pain. Am J Hosp Palliat Care. 2012;29(2):93\u20137. https:\/\/doi.org\/10.1177\/1049909111410414 .","journal-title":"Am J Hosp Palliat Care"},{"issue":"8","key":"662_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1049909110373240","volume":"27","author":"AE Yakovlev","year":"2010","unstructured":"Yakovlev AE, Resch BE, Karasev SA. Treatment of cancer-related chest wall pain using spinal cord stimulation. Am J Hosp Palliat Care. 2010;27(8):552\u20136. https:\/\/doi.org\/10.1177\/1049909110373240 .","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"662_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jpainsymman.2003.05.007","volume":"27","author":"JP Cata","year":"2004","unstructured":"Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM. Spinal cord stimulation relieves chemotherapy-induced pain: a clinical case report. J Pain Symptom Manag. 2004;27(1):72\u20138. https:\/\/doi.org\/10.1016\/j.jpainsymman.2003.05.007 .","journal-title":"J Pain Symptom Manag"},{"issue":"11","key":"662_CR43","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00701-009-0400-8","volume":"151","author":"B Clavo","year":"2009","unstructured":"Clavo B, Robaina F, Montz R, Carames MA, Lloret M, Ponce P, et al. Modification of glucose metabolism in radiation-induced brain injury areas using cervical spinal cord stimulation. Acta Neurochir. 2009;151(11):1419\u201325. https:\/\/doi.org\/10.1007\/s00701-009-0400-8 .","journal-title":"Acta Neurochir"},{"issue":"2","key":"662_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/AJP.0b013e3181839ad8","volume":"25","author":"MG Lee","year":"2009","unstructured":"Lee MG, Choi SS, Lee MK, Kong MH, Lee IO, Oh HR. Thoracic spinal cord stimulation for neuropathic pain after spinal meningioma removal: a case report. Clin J Pain. 2009;25(2):167\u20139. https:\/\/doi.org\/10.1097\/AJP.0b013e3181839ad8 .","journal-title":"Clin J Pain"},{"issue":"2","key":"662_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1533-2500.2007.00122.x","volume":"7","author":"JC Ting","year":"2007","unstructured":"Ting JC, Fukshansky M, Burton AW. Treatment of refractory ischemic pain from chemotherapy-induced Raynaud\u2019s syndrome with spinal cord stimulation. Pain Pract. 2007;7(2):143\u20136. https:\/\/doi.org\/10.1111\/j.1533-2500.2007.00122.x .","journal-title":"Pain Pract"},{"issue":"11","key":"662_CR46","first-page":"1460","volume":"58","author":"S Tsubota","year":"2009","unstructured":"Tsubota S, Higaki N, Nagaro T. A case of neuropathic cancer pain in the lower extremities successfully treated with spinal cord stimulation. Masui. 2009;58(11):1460\u20131.","journal-title":"Masui"},{"issue":"3\u20134","key":"662_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3121\/cmr.2008.813","volume":"6","author":"AE Yakovlev","year":"2008","unstructured":"Yakovlev AE, Ellias Y. Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clin Med Res. 2008;6(3\u20134):103\u20136. https:\/\/doi.org\/10.3121\/cmr.2008.813 .","journal-title":"Clin Med Res"},{"issue":"5","key":"662_CR48","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/annonc\/mdh189","volume":"15","author":"B Clavo","year":"2004","unstructured":"Clavo B, Robaina F, Catala L, Perez JL, Lloret M, Carames MA, et al. Effect of cervical spinal cord stimulation on regional blood flow and oxygenation in advanced head and neck tumours. Ann Oncol. 2004;15(5):802\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdh189 .","journal-title":"Ann Oncol"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-018-0662-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0662-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-018-0662-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T22:17:34Z","timestamp":1660429054000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-018-0662-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s11916-018-0662-z","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Fangfang Xing, R. Jason Yong, Alan David Kaye, and Richard Urman declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"11"}}